XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Lijia Pan, Zhixiang Wu|Journal of Experimental & Clinical Cancer Research|2021

Cited by 29